Biohaven Ltd. (BHVN)
WatchA data-driven read of BHVN's strengths and risk factors, built from its financials, earnings history, analyst activity, and insider trading, not opinion or speculation.
Five independent market signals, analysts, institutions, insiders, short sellers, and price trend, each scored from real, current data. See exactly where the smart money agrees, and where it's split.
All 5 available signals lean the same direction: bullish.
Every trading day in the last 2 years where BHVN moved 4% or more in a single session, most recent first, a quick read on how volatile this stock has really been. See full daily price history →
| Date | Move | Close |
|---|---|---|
| Aug 28, 2026 | -4.40% | $15.41 |
| Aug 27, 2026 | -4.90% | $16.12 |
| Aug 26, 2026 | +17.87% | $16.95 |
| Aug 25, 2026 | +5.12% | $14.38 |
| Aug 20, 2026 | -4.53% | $13.50 |
| Aug 6, 2026 | +5.80% | $14.42 |
| Jul 28, 2026 | -5.10% | $13.77 |
| Jul 22, 2026 | -4.90% | $14.75 |
| Jul 21, 2026 | +4.37% | $15.51 |
| Jul 17, 2026 | +8.96% | $15.44 |
| Jul 16, 2026 | -4.64% | $14.17 |
| Jul 10, 2026 | -7.39% | $15.55 |
| Jul 8, 2026 | +7.01% | $16.64 |
| Jul 1, 2026 | +5.91% | $15.76 |
| Jun 29, 2026 | -5.56% | $14.95 |
| Jun 23, 2026 | -4.65% | $14.78 |
| Jun 22, 2026 | +14.22% | $15.50 |
| Jun 17, 2026 | +12.66% | $13.62 |
| Jun 15, 2026 | +7.62% | $12.14 |
| Jun 5, 2026 | -5.26% | $10.80 |
| Jun 4, 2026 | +5.46% | $11.40 |
| Jun 3, 2026 | +6.71% | $10.81 |
| Jun 2, 2026 | -11.37% | $10.13 |
| May 29, 2026 | +7.52% | $11.01 |
| May 28, 2026 | -9.30% | $10.24 |
Showing the 25 most recent of 154 on record. Full history is on the Price Insights page.
Every major event from the past 12 months, earnings reports, insider transactions, and analyst upgrades or downgrades, merged into a single chronological feed so you can see what clustered together.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
215 Church Street, New Haven, CT, 06510, United States, 203 404 0410
Other Biotechnology companies tracked on this site, ranked by institutional ownership. Compare BHVN against its closest peers.
A complete statistical profile built from BHVN's full price, financial, and ownership history, not an isolated snapshot. Explore any category in depth below.